



Drug Discovery & Development Symposium 2025

Inclusive & sustainable drug
development for Pulmonary
Arterial Hypertension (PAH)

16 - 17 June 2025

Mercure Amsterdam City Hotel
Joan Muyskenweg 10, 1096 CJ,
Amsterdam, Netherlands



Inclusive & sustainable drug development for PAH

08:00-08:25 Welcome tea & coffee

08:25-08:30 Welcome
Anna Hemnes, PVRI President 2024-2026

SESSION 1: New standards of care

Moderators: Anna Hemnes, Harm Jan Bogaard

08:30-09:00 Global perspective on regulatory approval of Sotatercept
Representatives from FDA: Mitchel Psotka (virtual), EMA (TBC)

09:00-09:20 How Sotatercept will change the treatment algorithm
Luke Howard

09:20-09:40 Implications of a new background therapy for drug development
Marion Delcroix

09:40-10:00 Panel & delegate discussion
All session speakers & moderators

SESSION 2: Disease modification

Moderators: Zhi-Cheng Jing, Martin Wilkins

10:00-10:15 How to define or prove disease modification
Mark Toshner

10:15-10:40 Pro/con debate: Drug development in the post vasodilator era - including a demonstration of disease modification
Pro: TBC / Con: TBC

10:40-10:50 Panel & delegate discussion
All session speakers & moderators

10:50-11:10 Refreshment break

SESSION 3: Diversity & inclusion

Moderators: Gergely Meszaros, Esther Nossent

11:10-11:30 Addressing sex differences in treatment decisions & drug development
Deimante Hoppenot

11:30-11:50 How to include underrepresented patients into cardiovascular clinical trials
Cati Brown-Johnson

11:50-12:00 Panel & delegate discussion
All session speakers & moderators

SESSION 4: Global aspects of drug development & availability

Moderators: Anton Vonk-Noordegraaf, Deimante Hoppenot

- | | |
|-------------|--|
| 12:00-12:15 | Using the GoDeep Registry to prioritise & facilitate global drug trials
Werner Seeger |
| 12:15-12:40 | Pro/con debate: It is Big Pharma's responsibility to prioritise drug availability over drug discovery
Pro: Anna Hemnes / Con: Ardeshir Ghofrani (TBC) |
| 12:40-13:00 | Panel & delegate discussion
All session speakers & moderators |

13:00-14:00 **Lunch break**

SESSION 5: Innovations in trial design

Moderators: Athénaïs Boucly, Frances Varian

- | | |
|-------------|---|
| 14:00-14:20 | How to use risk scores (enrichment, endpoints)
Athénaïs Boucly |
| 14:20-14:40 | How to use imaging endpoints reflecting the pulmonary circulation & RV
David Kiely |
| 14:40-15:10 | n=1 trials & randomised withdrawal studies
Martin Wilkins |
| 15:10-15:30 | Panel & delegate discussion
All session speakers & moderators |

15:30-15:50 **Refreshment break**

- | | |
|-------------|---|
| 15:50-16:10 | Novel statistical approaches: Bayesian statistics, use of win ratio
Alex Rothman |
| 16:10-16:30 | Practical & ethical aspects around OLE studies
Harm Jan Bogaard |
| 16:30-16:50 | Climate impact of drug development
Frances Varian |
| 16:50-17:10 | Panel & delegate discussion
All session speakers & moderators |

17:10-19:00 **Networking drinks reception**

Scientific programme: 17 June

08:00-08:30 Welcome tea & coffee

SESSION 6: Novel drug & device therapies

Moderators: Frances de Man, Jurjan Aman

08:30-08:55 Antibody based inhibition of Endothelin signalling
Zhi-Cheng Jing

08:55-09:20 Elafin
Roham Zamanian (virtual)

09:20-09:45 Moslicigat
Ardeshir Ghofrani

09:45-10:10 New drugs to modify TGF- β receptor signalling
Paul Yu

10:10-10:40 Refreshment break

10:40-11:05 Seralutinib
Pilar Escribano Subías

11:05-11:30 Aria Device
Marc Pritzker

11:30-11:55 Pulmonary artery denervation
Alex Rothman

11:55-12:25 Closing statements

